leadf
logo-loader
viewVolitionRx

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to upcoming product launches

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019.

Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer Screening Test for dogs, on November 30th.

Quick facts: VolitionRx

Price: 3.79 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $199.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx hosts virtual capital markets day event to discuss upcoming...

VolitionRx Limited (NYSE AMERICAN: VNRX) CEO Cameron Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020. Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first...

on 10/20/2020

2 min read